News Releases

November 9, 2020

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company’s Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

April 22, 2020

OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020

OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020

OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.